Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Upper Respiratory Tract Infection

Conditions

Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea, Sneezing

Trial Timeline

Jul 1, 2013 → Aug 1, 2015

About Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets

Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tablets is a phase 3 stage product being developed by Novartis for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01448057. Target conditions include Upper Respiratory Tract Infection, Nasal Congestion, Rhinorrhea.

What happened to similar drugs?

6 of 14 similar drugs in Upper Respiratory Tract Infection were approved

Approved (6) Terminated (1) Active (8)
Remimazolam TosilateJiangsu Hengrui MedicineApproved
BOTOXAbbVieApproved
Montelukast + PlaceboMerckApproved
Diclofenac gelNovartisApproved
AboBoNT-A + OnaBoNT-AIpsenApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01448057Phase 3Completed

Competing Products

20 competing products in Upper Respiratory Tract Infection

See all competitors
ProductCompanyStageHype Score
Nivolumab 100 MG in 10 ML InjectionOno PharmaceuticalPhase 2
31
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
ABBV-950 + BOTOX + Placebo for ABBV-950AbbViePhase 1
21
BOTOX + Placebo for BOTOXAbbViePhase 2
35
BOTOXAbbVieApproved
43
MK-3475 and BCGMerckPhase 2
42
Montelukast + PlaceboMerckApproved
43
Muntelukast + PlaceboMerckPhase 3
36
IFF flavor 316 282, Paracetamol, PseudoephedrineNovartisPhase 3
40
diclofenac potassium + nimesulideNovartisApproved
35
Diclofenac gelNovartisApproved
43
IFF flavor 316 282, Paracetamol , Phenylephrine, GuaifenesinNovartisPhase 3
40
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + NivolumabGilead SciencesPhase 3
44
Azithromycin SRPfizerPhase 3
40
NivolumabBristol Myers SquibbPre-clinical
26
NivolumabBristol Myers SquibbPre-clinical
26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsPhase 2
27
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
AboBoNT-A + OnaBoNT-AIpsenApproved
40
Botulinum toxin type AIpsenPhase 3
37